The Wall Street Journal reported on a new study showing that the price of the 50 top-selling drugs rose an average of 7.8 percent last year. The article discusses efforts to contain drug costs for Medicare beneficiaries by having Medicare negotiate prices directly with the industry.
While it presents the argument of an analyst saying that Medicare could negotiate sharply lower drug prices, it also presents the assertion of a Bush administration official that Medicare would be unable to negotiate lower prices than the private insurers operating within the Medicare program. It would have been helpful to point out that the Veterans Administration gets prices that average 40 percent less than the prices paid by by the insurers operating within Medicare. There is no obvious reason that Medicare, which represents a much larger share of the market than the VA, would not be able to negotiate prices comparable to the prices negotiated by the VA. In fact, Medicare could even arrange to have the VA negotiate prices on its behalf.
A second Trump administration will cement a right-wing majority on the Supreme Court for a generation, and put our collective future in the hands of someone who will be virtually unchecked by our institutions. The country has shifted rightward, and the reverberations will ensue for potentially the next few decades. In this climate, a robust independent media ecosystem will be more important than ever. We're committed to bringing you the latest news on how Trump's agenda will actually affect the American people, shining a light on the stories corporate media overlooks and keeping the public informed about how power really works in this country.
Quality journalism is expensive to produce, and we don't have corporate backers to rely on to fund what we do. Everything we do is thanks to our incredible community of readers, who chip in a few dollars at a time to make our work possible. Any amount you give today will help us continue reporting on what matters to our democracy.
